Jobs Tenders Contact Us
Skip Navigation LinksHome > Campuses > About Bengaluru Campus > Major Achievements

Major Achievements

  • Pioneered introduction of FMD vaccine production using fermentation technology in India.
  • Established improved animal diagnostic reagents platform for developing assays to detect infectious diseases using baculovirus virus system or monoclonal antibody technology. Improvement in diagnostics for FMD, PPR, Bluetongue was carried out through collaboration.
  • Developed and commercialized FMDV recombinant protein 3ABC based in-house indirect ELISA (iELISA) and a lateral flow based rapid diagnostic for differentiating infected from vaccinated animals (DIVA test).
  • A highly sensitive monoclonal antibody-based blocking ELISA for detection of FMD NSP antibodies in multispecies of animals susceptible to FMD was developed, validated and technology released.
  • Evaluated an improved thermostable mutant (IND R2/1975mut) FMD serotype O vaccine strain under a collaborative project between ICAR-IVRI and ICAR-Directorate of FMD with satisfactory performance over in-use vaccine strain in cattle. Efficacy studies using a thermostable serotype O vaccine candidate in trivalent form are underway.
  • A recombinant deletion mutant of serotype A FMD virus was evaluated as a DIVA-enabled negative marker vaccine candidate which induced potent immune response with 100% protective efficacy upon challenge with homologous virus on par with the parental vaccine strain. Similarly negative marker vaccine candidate for FMDV Asia1 is produced using cDNA approach for improved DIVA application.
  • Developed a proof of concept that single dose vaccination with novel adjuvanted vaccine could provide protection for FMD for 12 months.
  • Providing technical backstopping to DAHD,GOI for having an effective FMD vaccine quality control mechanism for the country and the SAARC region.
  • Efficacy studies using FMD & HS combined vaccine are underway.
  • Developed serology based alternative assays for potency testing of vaccine batches
  • LPB-ELISA which is widely used for seromonitoring following FMD vaccination has been improved by including a monoclonal antibody that replaces serotype dependent tracing guinea pig antibody.
  • Virus like particles (VLPs) of FMDV serotype O, A and Asia 1 were produced in insect cells and evaluated for their potential as diagnostic reagents and immunogens.